We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -94.00 | -0.80% | 11,624.00 | 11,648.00 | 11,652.00 | 11,710.00 | 11,540.00 | 11,688.00 | 11,353,499 | 16:35:02 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5371 | 25.68 | 181.69B |
From Feb 2020 to Feb 2025
LONDON--Drug development company Synairgen PLC (SNG.LN) said Wednesday that AstraZeneca PLC (AZN.LN) has decided to stop the clinical trial of asthma treatment drug AZD9412, or inhaled interferon beta-1a.
The company said Astra halted the trial because of difficulty in determining primary endpoint as there were very low number of severe exacerbations overall. AstraZeneca will now review the data and study design before deciding on the best way forward for the program, the company added.
The AZD9412 program was developed by Synairgen and licensed to Astra in June 2014.
Shares of Synairgen at 0745 GMT trading 33.8% lower at 23 pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
October 12, 2016 04:02 ET (08:02 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
